Enovis (ENOV) Competitors

Enovis (NYSE:ENOV) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, community ranking, institutional ownership, profitability, dividends and analyst recommendations.

Does the MarketBeat Community favor ENOV or GKOS?

Glaukos received 421 more outperform votes than Enovis when rated by MarketBeat users. Likewise, 65.03% of users gave Glaukos an outperform vote while only 61.70% of users gave Enovis an outperform vote.

Company	Underperform	Outperform
Enovis	Outperform Votes 29 61.70%	Underperform Votes 18 38.30%
Glaukos	Outperform Votes 450 65.03%	Underperform Votes 242 34.97%

Do institutionals & insiders have more ownership in ENOV or GKOS?

98.4% of Enovis shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 2.4% of Enovis shares are held by insiders. Comparatively, 6.4% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media refer more to ENOV or GKOS?

In the previous week, Glaukos had 19 more articles in the media than Enovis. MarketBeat recorded 25 mentions for Glaukos and 6 mentions for Enovis. Enovis' average media sentiment score of 1.24 beat Glaukos' score of 0.29 indicating that Enovis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	5 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has higher earnings and valuation, ENOV or GKOS?

Enovis has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.00B	1.21	-$33.26M	-$2.19	-19.53
Glaukos	$314.71M	22.08	-$134.66M	-$3.02	-41.73

Do analysts recommend ENOV or GKOS?

Enovis currently has a consensus target price of $64.83, suggesting a potential upside of 51.60%. Glaukos has a consensus target price of $163.25, suggesting a potential upside of 29.53%. Given Enovis' higher probable upside, analysts clearly believe Enovis is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Glaukos	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Is ENOV or GKOS more profitable?

Enovis has a net margin of -5.95% compared to Glaukos' net margin of -42.43%. Enovis' return on equity of 4.39% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-5.95%	4.39%	2.80%
Glaukos	-42.43%	-18.99%	-11.47%

Which has more volatility and risk, ENOV or GKOS?

Enovis has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Summary

Enovis beats Glaukos on 10 of the 19 factors compared between the two stocks.